VENT 05
Alternative Names: VENT-05; VNX-05Latest Information Update: 05 Jan 2023
At a glance
- Originator Ventus Therapeutics
- Class Small molecules
- Mechanism of Action NLRP3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cardiovascular disorders; Kidney disorders; Liver disorders
- Research Neurological disorders
Most Recent Events
- 12 Oct 2022 Preclinical trials in Cardiovascular disorders in USA (unspecified route) (Ventus Therapeutics pipeline, October 2022)
- 12 Oct 2022 Preclinical trials in Kidney disorders in USA (unspecified route) (Ventus Therapeutics pipeline, October 2022)
- 12 Oct 2022 Preclinical trials in Liver disorders in USA (unspecified route) (Ventus Therapeutics pipeline, October 2022)